Mirebax (Rivaroxaban)

Rivaroxaban, the active ingredient in Mirebax, is a Direct Factor Xa inhibitor presented as an oral dosage form for oral use. It is indicated for preventing stroke and systemic embolism in patients with non‑valvular atrial fibrillation and for treating and preventing deep vein thrombosis and pulmonary embolism. It is approved for use in the European Union market.

GNH USA supplies Mirebax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Mirebax (rivaroxaban) acts on the coagulation cascade by selectively inhibiting Factor Xa, reducing thrombin generation. - Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism. - Deep vein thrombosis (DVT): treats acute clot formation and facilitates clot resolution. - Pulmonary embolism (PE): treats acute embolic events and prevents recurrence. - Recurrent DVT/PE: provides secondary prevention of further thrombotic episodes. - Orthopedic surgery prophylaxis: lowers incidence of postoperative DVT and PE after hip or knee replacement.

Mirebax may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Minor bleeding (e.g., bruising, nosebleeds) - Headache - Nausea or dyspepsia - Diarrhea

Serious or Rare Side Effects: - Severe or uncontrolled bleeding (intracranial, gastrointestinal) - Spinal or epidural hematoma - Liver enzyme elevation or hepatic injury - Anaphylactic or severe allergic reaction

Before initiating Mirebax, clinicians should evaluate several patient‑specific factors to minimize bleeding risk and ensure appropriate use. - Renal impairment: assess kidney function and adjust dose or avoid in severe cases. - Hepatic disease: use with caution in patients with moderate to severe liver dysfunction. - Concomitant anticoagulants or antiplatelet agents: increased bleeding risk, consider dose modification or alternative therapy. - Upcoming surgery or invasive procedures: discontinue Mirebax according to recommended interval before the procedure. - Pregnancy or lactation: avoid unless benefits outweigh potential risks, and consult obstetric guidance. - Store at ambient temperature: keep in original packaging, protect from moisture and excessive heat.

Mirebax interacts with several medicines that can alter its anticoagulant effect or increase bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise rivaroxaban plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce anticoagulant efficacy. - Concurrent use with other anticoagulants (e.g., warfarin, heparin): markedly increases bleeding risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive effect on bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: heightened risk of hemorrhage. - Antiplatelet agents (e.g., clopidogrel, aspirin): may require dose adjustment or close monitoring.